Form 4: MAIA Biotechnology Director Stan Smith Reports Stock Option Grant

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a grant under the company's 2021 Equity Incentive Plan.

Summary

• On March 31, 2024, Stan Smith, a director of MAIA Biotechnology, Inc., reported the acquisition of 11,491 stock options.
• These options were granted pursuant to the company's 2021 Equity Incentive Plan.
• The options vest immediately and are exercisable from the grant date.
• The exercise price of the options is $2.2.
• The options expire on March 31, 2034.
• Smith also indirectly owns 11,491 shares of common stock through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The grant of options is neither inherently positive nor negative, but rather a standard part of executive compensation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting of the options could incentivize the director to contribute to the company's success.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The stock option grant could potentially align the director's interests with those of the shareholders, incentivizing them to increase shareholder value.

Key Dates